Arias-Reyes J A, Matos-Martínez M, Velásquez-Jones L, Dubey-Ortega L A
Bol Med Hosp Infant Mex. 1989 Sep;46(9):603-6.
In order to evaluate the efficiency of albuterol sulfate (salbutamol) in lowering of potassium levels in uremic children with hyperkalemia, we intravenously administered salbutamol 30 micrograms/min (total doses 0.5 mg) to ten children with chronic renal failure (CRF) with high serum levels of potassium. Forty five minutes after administration, potassium serum levels were lower going from 6.79 +/- 0.57 mmol/L to 5.04 +/- 1.10 mmol/L; increasing levels were documented 6 hours later up to 5.76 +/- 0.66 mmol/L. Lowering in potassium serum levels was associated with disappearance of electrocardiographic manifestations of hyperkalemia. We observed moderated tachycardia in 90% of our patients and only one patient required withdrawal of this drug for high cardiac frequency rate. We conclude that salbutamol is a useful and safe choice in treatment of hyperkalemia in children with CRF.
为了评估硫酸沙丁胺醇（舒喘灵）降低尿毒症高钾血症患儿血钾水平的效果，我们对10名血清钾水平高的慢性肾衰竭（CRF）患儿静脉注射沙丁胺醇，速度为30微克/分钟（总剂量0.5毫克）。给药45分钟后，血清钾水平下降，从6.79±0.57毫摩尔/升降至5.04±1.10毫摩尔/升；6小时后记录到血钾水平升高，高达5.76±0.66毫摩尔/升。血清钾水平的降低与高钾血症心电图表现的消失相关。我们观察到90%的患者出现中度心动过速，只有1名患者因心率过快需要停用该药。我们得出结论，沙丁胺醇是治疗CRF患儿高钾血症的一种有用且安全的选择。
